The pharmacotherapeutic approaches of the various diabetes models evaluated, including the use of insulin and non-insulin agents like aminoguanidine, Voglibose, sitagliptin, exenatide, and metformin, reveal conflicting short-term outcomes. This evidence concerns the gene INS and diabetes mellitus.